Targeting Africa, circumcision device gets positive safety data; Device offers one-hour bacteria Dx;

@FierceMedDev: An FDA panel says the cons outweigh the pros with metal-on-metal hip replacements. Item | Follow @FierceMedDev

 @MarkHFierce: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @MarkHFierce

 @DamianFierce: U.K. regulators are warning hospitals about infection risks with reusable medical devices. Story | Follow @DamianFierce

> Researchers are reporting positive safety results for the Shang Ring, a male circumcision device under development to increase access to the procedure in AIDS-affected parts of Africa. The tech's development is funded in part by the Bill & Melinda Gates Foundation. More

> Belgian diagnostics firm MDxHealth is launching an equity offering to raise €10 million ($12.6 million). Item

> DxUpClose is developing a diagnostic device that can screen for bacterial infections and determine the ideal antibiotic to treat it, all within an hour. Article

> Brolex is expanding the use of its C Safe device, designed to minimize risk to babies in cesarean sections, to 7 countries around the world. News

> Svelte Medical Systems, looking to develop a next-generation stent for cardiac surgery, brought down $8 million in financing. Item

Biotech News

 @FierceBiotech: At GSK, there are no corner offices, or any other. More | Follow @FierceBiotech

 @JohnCFierce: Icahn step 5: Sue Forest over succession plan. More | Follow @JohnCFierce

> Biogen Idec offers up to $271M for its second Isis pact. Story

> Astellas nabs critical FDA OK for new overactive bladder pill mirabegron. Article

> BioInvent forced to reorganize, ax staffers in wake of study failure. News

Pharma News

 @FiercePharma: So, what's with all the drug names ending in "IQ"? Astellas' Myrbetriq, Arena's Belviq ... Did Pfizer's Pristiq start a trend? | Follow @FiercePharma

> FDA says yes to Astellas' bladder drug Myrbetriq. Article

> GSK again extends its $2.6 billion bid for HGS. Story

> Generic antiviral market poised to boom. More

> Icahn says CEO treating Forest like a dynasty. News

Suggested Articles

AI-based drug molecule designer XtalPi has secured a mammoth funding round totaling $318.8 million, from global banking and tech investors.

LabCorp has licensed a blood test from Genfit designed to identify patients with risky cases of the liver disease NASH.

Philips has launched a compact, single-use device for physically clearing potentially dangerous blood clots lodged in the arms and legs.